Pharsight

Drugs that contain Maraviroc

1. Selzentry patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6586430 VIIV HLTHCARE CCR5 modulators
Dec, 2019

(4 years ago)

US7576097 VIIV HLTHCARE Tropane derivatives useful in therapy
May, 2021

(2 years ago)

US6667314 VIIV HLTHCARE Tropane derivatives useful in therapy
Aug, 2021

(2 years ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7576097

(Pediatric)

VIIV HLTHCARE Tropane derivatives useful in therapy
Nov, 2021

(2 years ago)

US6667314

(Pediatric)

VIIV HLTHCARE Tropane derivatives useful in therapy
Feb, 2022

(2 years ago)

US7368460 VIIV HLTHCARE Tropane derivatives useful in therapy
Nov, 2022

(1 year, 4 months ago)

US7368460

(Pediatric)

VIIV HLTHCARE Tropane derivatives useful in therapy
May, 2023

(10 months ago)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) May 28, 2013
New Strength(NS) Nov 04, 2019
New Chemical Entity Exclusivity(NCE) Aug 06, 2012

NCE-1 date: 07 August, 2011

Market Authorisation Date: 04 November, 2016

Treatment: Method of treating patients infected with ccr5-tropic hiv-1

Dosage: TABLET;ORAL; SOLUTION;ORAL

How can I launch a generic of SELZENTRY before it's drug patent expiration?
More Information on Dosage

SELZENTRY family patents

Family Patents